0
0
ISLAMABAD — A volatile geopolitical landscape in the Middle East is beginning to cast a long shadow over Pakistan’s healthcare sector. As of April 2026, intensified conflict involving the United States, Iran, and Israel has disrupted critical maritime shipping routes, leading to a surge in freight costs and logistical bottlenecks. These disruptions are now testing the resilience of Pakistan’s health supply chains, sparking concerns among industry leaders and public health experts over the availability of essential medicines and infant formula.
While federal health officials maintain that there is no immediate nationwide collapse, the pharmaceutical industry warns that the country’s heavy reliance on imported raw materials—many of which transit through the now-unstable Gulf routes—leaves the population vulnerable to a “slow-burn” shortage.
The Dependency Dilemma: Imports and Raw Materials
The crux of the current anxiety lies in the pharmaceutical sector’s structure. Although the Drug Regulatory Authority of Pakistan (DRAP) reports that approximately 85% of medicines consumed in the country are manufactured locally, this figure is somewhat misleading regarding self-sufficiency. Local manufacturing remains deeply dependent on the import of Active Pharmaceutical Ingredients (APIs)—the raw chemical components required to produce finished drugs.
Industry estimates from March and April 2026 suggest that stocks of these essential raw materials may only last between 45 to 60 days if supply lines remain constricted.
“The immediate concern isn’t that the shelves are empty today,” says Abdul Samad Budhani, Chairman of the Pakistan Chemist & Drug Association. “The concern is the replenishment. Domestic stocks of many essential medicines may last only about two months, and infant formula, which is largely imported as a finished product, is even more exposed to these shipping delays.”
Specialized Care at Risk
While general medications remain available for now, the pressure is most acute for life-saving treatments that require specific, often temperature-sensitive, imported inputs. Health advocates point to several high-risk categories:
-
Chronic Diseases: Insulin for diabetes and specialized medications for heart disease and hypertension.
-
Critical Care: Oncology (cancer) treatments and vaccines.
-
Pediatric Health: Treatments for childhood tuberculosis and specialized nutritional products.
Mohammad Atif Hanif Baloch, President of the Wholesale Chemists Council of Pakistan, has warned that if the conflict persists, the cost of these life-saving drugs could rise sharply due to increased insurance and freight surcharges, potentially placing them out of reach for low-income households.
The Infant Formula Crisis: A Vulnerable Population
Beyond pharmacy shelves, the shortage is hitting grocery aisles in the form of dwindling infant formula stocks. Unlike many medicines, a significant portion of infant formula in Pakistan is imported as a finished commercial product.
The World Health Organization (WHO) issued a statement in March 2026 highlighting that international supply chain disruptions and traceability issues are particularly risky for infants—the most vulnerable demographic. While the WHO emphasizes that breastfeeding should be the first line of defense in emergencies, they acknowledge that formula is a medical necessity for infants who cannot be breastfed or who require specialized nutrition.
The Danger of “Improvisation”
Public health experts warn that formula scarcity often leads to dangerous household workarounds. When a specific brand disappears or prices spike, caregivers may resort to:
-
Over-dilution: Adding extra water to stretch a tin of formula, which leads to malnutrition and electrolyte imbalances.
-
Unsafe Substitutes: Using cow’s milk, tea, or “homemade” formulas that lack the precise nutrient balance required for infant brain and body development.
-
Rapid Switching: Abruptly changing formulas can cause significant gastrointestinal distress in sensitive infants.
Government Response vs. Industry Warnings
The Pakistani government has moved to temper public anxiety. Health Minister Syed Mustafa Kamal addressed the situation in late March, stating that there was no immediate shortage at the time and expressing a goal to eventually increase national stockpiles to a six-month buffer.
DRAP has also been active in monitoring price hikes, disputing claims that essential medicine prices have officially been raised due to the conflict. The authority continues to utilize its shortage-reporting systems to track availability at the hospital level.
However, a gap remains between official reassurances and “boots-on-the-ground” reports from chemists. This discrepancy is common in supply chain crises; shortages often manifest as regional “spot shortages” before becoming a visible national emergency.
A Call for Resilience and Resourcefulness
The current situation serves as a stark reminder that health security is inextricably linked to global trade stability. For Pakistan, the path forward involves more than just weathering the current storm; it requires a structural shift toward diversifying import routes and incentivizing the domestic production of APIs to reduce vulnerability to external shocks.
Guidance for the Public
Healthcare providers are urging calm and prepared action rather than panic:
-
Avoid Panic Buying: Hoarding medication worsens shortages for others and can lead to drugs expiring unused.
-
Consult Professionals: If a specific medication or formula is unavailable, consult a physician or pharmacist for an approved alternative. Never attempt to “make your own” medical solutions.
-
Maintain Prescriptions: Ensure you have current, valid prescriptions and stay in regular contact with your primary care provider.
As the conflict in the Middle East continues, the next several weeks will be a critical period for Pakistan’s health infrastructure. Whether the current warnings remain “potential risks” or transition into a full-scale crisis depends heavily on the duration of shipping disruptions and the government’s ability to facilitate emergency supply routes.
Medical Disclaimer
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
Primary News & Industry Sources:
-
Pakistan Observer, “US-Iran war: Pakistan’s pharmaceutical gaps,” March 2026.
-
Free Press Journal, Reports on pharmaceutical input disruptions and Gulf-linked routes, March 2026.
-
Arab News, Interview with Health Minister Syed Mustafa Kamal on medicine stockpiles, March 2026.
